These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 33230039)

  • 1. Current advances in giant cell arteritis.
    Kaushik M; Ponte C; Mollan SP
    Curr Opin Neurol; 2021 Feb; 34(1):133-141. PubMed ID: 33230039
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An update on the clinical approach to giant cell arteritis.
    Piccus R; Hansen MS; Hamann S; Mollan SP
    Clin Med (Lond); 2022 Mar; 22(2):107-111. PubMed ID: 35304369
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Giant cell arteritis: reviewing the advancing diagnostics and management.
    Bilton EJ; Mollan SP
    Eye (Lond); 2023 Aug; 37(12):2365-2373. PubMed ID: 36788362
    [TBL] [Abstract][Full Text] [Related]  

  • 4. European Headache Federation recommendations for neurologists managing giant cell arteritis.
    Mollan SP; Paemeleire K; Versijpt J; Luqmani R; Sinclair AJ
    J Headache Pain; 2020 Mar; 21(1):28. PubMed ID: 32183689
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Challenges of diagnosis and management of giant cell arteritis in general practice: a multimethods study.
    Helliwell T; Muller S; Hider SL; Prior JA; Richardson JC; Mallen CD
    BMJ Open; 2018 Feb; 8(2):e019320. PubMed ID: 29431135
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Treatment of giant cell arteritis: what is in the pipeline?].
    Holle JU; Moosig F
    Z Rheumatol; 2020 Aug; 79(6):516-522. PubMed ID: 32399619
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Cost-Effectiveness of Tocilizumab (Actemra) Therapy in Giant Cell Arteritis.
    Jogimahanti AV; Kini AT; Irwin LE; Lee AG
    J Neuroophthalmol; 2021 Sep; 41(3):342-350. PubMed ID: 34415267
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Does glucocorticosteroid-resistant large-vessel vasculitis (giant cell arteritis and Takayasu arteritis) exist and how can remission be achieved? A critical review of the literature.
    Kötter I; Henes JC; Wagner AD; Loock J; Gross WL
    Clin Exp Rheumatol; 2012; 30(1 Suppl 70):S114-29. PubMed ID: 22640655
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relapses in giant cell arteritis: Updated review for clinical practice.
    Alba MA; Kermani TA; Unizony S; Murgia G; Prieto-González S; Salvarani C; Matteson EL
    Autoimmun Rev; 2024 Jun; 23(6):103580. PubMed ID: 39048072
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of intracranial vasculitis in giant cell arteritis during tocilizumab treatment.
    Naderi N
    Clin Exp Rheumatol; 2020; 38 Suppl 124(2):207-209. PubMed ID: 32359040
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of Giant Cell Arteritis and Takayasu Arteritis-Current and Future.
    Hellmich B; Águeda AF; Monti S; Luqmani R
    Curr Rheumatol Rep; 2020 Oct; 22(12):84. PubMed ID: 33044642
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biological treatments in giant cell arteritis & Takayasu arteritis.
    Samson M; Espígol-Frigolé G; Terrades-García N; Prieto-González S; Corbera-Bellalta M; Alba-Rovira R; Hernández-Rodríguez J; Audia S; Bonnotte B; Cid MC
    Eur J Intern Med; 2018 Apr; 50():12-19. PubMed ID: 29146018
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tocilizumab in Giant Cell Arteritis: A Multicenter Retrospective Study of 34 Patients.
    Régent A; Redeker S; Deroux A; Kieffer P; Ly KH; Dougados M; Liozon E; Larroche C; Guillevin L; Bouillet L; Espitia O; Costedoat-Chalumeau N; Soubrier M; Brihaye B; Lifermann F; Lefevre G; Puéchal X; Mouthon L; Toussirot E;
    J Rheumatol; 2016 Aug; 43(8):1547-52. PubMed ID: 27182063
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current and emerging diagnosis tools and therapeutics for giant cell arteritis.
    González-Gay MA; Pina T; Prieto-Peña D; Calderon-Goercke M; Blanco R; Castañeda S
    Expert Rev Clin Immunol; 2018 Jul; 14(7):593-605. PubMed ID: 29877748
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current management of giant cell arteritis and its complications.
    Galli E; Muratore F; Warrington KJ
    Curr Opin Rheumatol; 2024 Sep; 36(5):344-350. PubMed ID: 38920090
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatments for giant cell arteritis: Meta-analysis and assessment of estimates reliability using the fragility index.
    Berti A; Cornec D; Medina Inojosa JR; Matteson EL; Murad MH
    Semin Arthritis Rheum; 2018 Aug; 48(1):77-82. PubMed ID: 29496228
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recent Advances in Giant Cell Arteritis.
    Guevara M; Kollipara CS
    Curr Rheumatol Rep; 2018 Apr; 20(5):25. PubMed ID: 29611005
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Update on giant cell arteritis.
    Sammel AM; Fraser CL
    Curr Opin Ophthalmol; 2018 Nov; 29(6):520-527. PubMed ID: 30138144
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of giant cell arteritis.
    González-Gay MÁ; Pina T; Prieto-Peña D; Calderon-Goercke M; Gualillo O; Castañeda S
    Biochem Pharmacol; 2019 Jul; 165():230-239. PubMed ID: 31034796
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of biologics in the treatment of giant cell arteritis.
    González-Gay MA; Pina T; Prieto-Peña D; Calderon-Goercke M; Blanco R; Castañeda S
    Expert Opin Biol Ther; 2019 Jan; 19(1):65-72. PubMed ID: 30513026
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.